ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1330

Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear

Marcela Ferrada1, Shubhasree D Choudhury2, Kam Newman2, Ninet Sinaii3, Monica Guma4, Thomas Christie5 and James D. Katz2, 1Critical Care, National Institutes of Health, Bethesda, MD, 2NIAMS, National Institutes of Health, Bethesda, MD, 3Clinical Center, National Institutes of Health, Bethesda, MD, 4Medicine, UCSD, La Jolla, CA, 5Relapsing Polychondritis Awareness and Support Foundation, Anoka, MN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: international

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a rare and in some cases fatal autoimmune disease that can affect multiple organs including cartilaginous structures. The disease is unpredictable and clinical manifestations may be variable resulting in a delay to diagnosis. Patients may have involvement of organs other than the nasal bridge and ear, including larynx, tracheobronchial tree, joints, vasculature, heart valves and kidneys. In this report we present the results of the largest survey to date evaluating disease patterns in an international cohort.

Methods: Data was acquired using an internet-based questionnaire aimed at cataloguing a variety of possible clinical presentations of RP. We obtained an Office of Human Subjects Research Protections ‘Exclusion from IRB Review’ certificate. The data was anonymous therefore met criteria for exclusion per the requirements of 45 CFR 46 and NIH policy. The Relapsing Polychondritis Awareness and Support Foundation administered the survey by email solicitation to patients that previously agreed to be contacted and by posting the link online. The survey was open to the public on 2/23/2016 and the data for this analysis was extracted on 4/11/2016.

Results: 193 surveys total were captured and 13 were excluded either for age less than 18 or no age reported. 180 surveys were included in this analysis. The mean age was 49.5 (SD 11.9). 86.5% were female. 91% identified as “white” and 31.5% reported country of origin other than the USA. The approximate mean age at diagnosis was 43.4 years (SD 12.7). A non-rheumatologist physician made the diagnosed in 47.5%. 54% of the patients saw more than 3 physicians prior to establishing a diagnosis and only 15% underwent cartilage biopsy to support the diagnosis. 49% of the patients had symptoms for more than 3 year before diagnosis. 55% of patients went to the emergency room prior to diagnosis because of RP symptoms.  Common initial symptoms included dizziness, eye inflammation, constochondritis, and shortness of breath, nose pain, and voice changes. Some patients also reported fatigue, flu-like symptoms, fever and difficulty swallowing as initial symptoms. Complications of RP included disability (25%), tracheomalacia (16%) and intubation related to RP (12%).  

Conclusion: This is the largest RP study to collate patient and disease characteristics in an international self-reported cohort. We found that the majority was female and there was a high incidence of initial symptoms other than ear and nose inflammation. The time to diagnosis was greater than 5 years. We learned that non-rheumatologist physicians commonly encounter patients with RP and sometimes these encounters occur in the emergency room. We also found that RP could have devastating complications including tracheomalacia and disability. Physicians must be alert to underappreciated presenting symptoms such as voice changes and shortness of breath. The limitations of this study include both the inability to validate self-reported claims of a diagnosis of RP and recall bias. The strength of our study includes the anonymous web-based strategy, which enabled us to capture a larger, and less geographically constrained, population.


Disclosure: M. Ferrada, None; S. D. Choudhury, None; K. Newman, None; N. Sinaii, None; M. Guma, None; T. Christie, Relapsing Polychondritis Awareness and Support Foundation, 6; J. D. Katz, None.

To cite this abstract in AMA style:

Ferrada M, Choudhury SD, Newman K, Sinaii N, Guma M, Christie T, Katz JD. Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/clinical-presentations-of-relapsing-polychondritis-more-than-a-swollen-ear/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-presentations-of-relapsing-polychondritis-more-than-a-swollen-ear/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology